# Vertex Pharmaceuticals (VRTX) — News

VRTX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vrtx/news

## Recent headlines

- [Bio-pharmaceutical stocks rose in regular trading, with Eli Lilly up 3.9%, Vertex Pharmaceuticals gaining 1.6% and Regeneron Pharmaceuticals rising 2.1%.](https://www.ainvest.com/news/bio-pharmaceutical-stocks-rose-regular-trading-eli-lilly-3-9-vertex-pharmaceuticals-gaining-1-6-regeneron-pharmaceuticals-rising-2-1-2610) — AInvest Wire, Oct 14, 2026
- [Frazier Life Sciences Acquisition Corp II prices IPO at $10/shr](https://www.ainvest.com/news/frazier-life-sciences-acquisition-corp-ii-prices-ipo-10-shr-2610) — AInvest Wire, Oct 14, 2026
  Frazier Life Sciences Acquisition Corp II (FLACU) has priced its initial public offering at $10 per share, raising capital for its targeted investments in the biotechnology sector. The company, part of the broader Frazier Life Sciences platform, is managed by extensive experience in healthcare .…
- [Bio-pharmaceutical stocks fell in regular trading, with Vertex Pharmaceuticals down 3.7%, AbbVie falling 2.4% and Merck sliding 2.2%.](https://www.ainvest.com/news/bio-pharmaceutical-stocks-fell-regular-trading-vertex-pharmaceuticals-3-7-abbvie-falling-2-4-merck-sliding-2-2-2610-65) — AInvest Wire, Oct 13, 2026
- [Vertex Pharmaceuticals Incorporated: BofA global research cuts price objective to $667 from $672](https://www.ainvest.com/news/vertex-pharmaceuticals-incorporated-bofa-global-research-cuts-price-objective-667-672-2610) — AInvest Wire, Oct 12, 2026
  Vertex Pharmaceuticals Incorporated (VRTX) has seen a recent adjustment in its price objective by BofA Global Research, which reduced its target to $667 from $672. This change, while modest, reflects ongoing evaluations of the company's stock potential amid evolving market conditions and…
- [Bio-pharmaceutical stocks fell in regular trading, with Regeneron down 2.7%, Vertex Pharmaceuticals falling 1.7% and Amgen sliding 1.7%.](https://www.ainvest.com/news/bio-pharmaceutical-stocks-fell-regular-trading-regeneron-2-7-vertex-pharmaceuticals-falling-1-7-amgen-sliding-1-7-2610) — AInvest Wire, Oct 1, 2026
  Bio-pharmaceutical stocks experienced declines in regular trading on October 1, 2026, with Regeneron Pharmaceuticals (REGN) down 2.7%, Vertex Pharmaceuticals (VRTX) falling 1.7%, and Amgen (AMGN) also sliding 1.7%. The sector has been under pressure amid ongoing challenges related to competitive…

## Similar Stocks

- [CRSP](https://www.lighthorse.io/tickers/crsp) — CRISPR Therapeutics AG - Common Shares
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [GOOG](https://www.lighthorse.io/tickers/goog) — Alphabet Inc. - Class C Capital Stock
- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [AMZN](https://www.lighthorse.io/tickers/amzn) — Amazon.com, Inc. - Common Stock
- [AXSM](https://www.lighthorse.io/tickers/axsm) — Axsome Therapeutics, Inc. - Common Stock
- [ISRG](https://www.lighthorse.io/tickers/isrg) — Intuitive Surgical, Inc. - Common Stock
- [EDIT](https://www.lighthorse.io/tickers/edit) — Editas Medicine, Inc. - Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).